Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
CC transcript
Quarterly results
Insys Therapeutics, Inc. (INSY) Create: Alert

All | News | Filings
Date FiledTypeDescription
03/07/2019 8-K Quarterly results
11/05/2018 8-K Quarterly results
Docs: "INSYS Therapeutics Reports Third Quarter 2018 Results Company’s Position as a Leader and Strategic Partner in Pharmaceutical Cannabinoids Strengthens with Involvement in Seven CBD Clinical Trials"
08/08/2018 8-K Quarterly results
Docs: "INSYS Therapeutics Reports Second Quarter 2018 Results Focus remains on advancing pipeline across cannabinoid and spray platforms"
11/02/2017 8-K Quarterly results
Docs: "Insys Therapeutics Reports Third Quarter 2017 Results Official Launch of SYNDROS ® and Filing NDA for Buprenorphine Sublingual Spray Drive Progress on Strategic Initiatives"
08/03/2017 8-K Quarterly results
Docs: "Insys Therapeutics Reports Second Quarter 2017 Results"
05/09/2017 8-K Form 8-K - Current report
04/03/2017 8-K Form 8-K - Current report
11/03/2016 8-K Form 8-K - Current report
08/03/2016 8-K Form 8-K - Current report
04/28/2016 8-K Form 8-K - Current report
02/23/2016 8-K Quarterly results
Docs: "Insys Therapeutics Reports Fourth Quarter and Year End 2015 Results"
11/05/2015 8-K Quarterly results
Docs: "Insys Therapeutics Reports Record Third Quarter 2015 Results",
"Insys Therapeutics Announces Stock Repurchase Program"
08/06/2015 8-K Quarterly results
Docs: "INSYS THERAPEUTICS, INC. CONDENSED CONSOLIDATED INCOME STATEMENTS Three Months Ended June 30, Six Months Ended June 30, 2015 2014 2015 2014 Net revenue $ 77,634 $ 55,696 $ 148,403 $ 97,332 Cost of revenue 8,305 6,555 14,680 11,328 Gross profit 69,329 49,141 133,723 86,004 Operating expenses: Sales and marketing 21,987 14,077 42,902 25,695 Research and development 17,796 9,189 28,398 13,197 General and administrative 15,284 10,689 28,531 19,257 Charges related to litigation award 2,304 - 10,304 - Total operating expenses 57,371 33,955 110,135 58,149 Income from operations 11,958 15,186 23,588 27,855 Other income ,net 30 - 30 2 Interest income 106 26 231 43 Income before income taxes 12,094 15,212 23,849 27,900 Income tax expense 4,779 5,747 8,512 10,777 Net income $ 7,315 $ 9,465 $ 15,337 ..."
05/07/2015 8-K Quarterly results
Docs: "INSYS THERAPEUTICS, INC. CONDENSED CONSOLIDATED INCOME STATEMENTS Three Months Ended March 31, 2015 2014 Net revenue $ 70,770 $ 41,636 Cost of revenue 6,375 4,773 Gross profit 64,395 36,863 Operating expenses: Sales and marketing 20,916 11,618 Research and development 10,602 4,008 General and administrative 21,246 8,568 Total operating expenses 52,764 24,194 Income from operations 11,631 12,669 Other income ,net - 13 Interest income , net 125 6 Income before income taxes 11,756 12,688 Income tax expense 3,733 5,030 Net income $ 8,023 $ 7,658 Net income per common share: Basic $ 0.23 $ 0.23 Diluted $ 0.21 $ 0.21 Shares used in computing net income per common share: Basic 35,458,414 33,566,416 Diluted 37,459,159 36,902,578 Percentage of Net revenue: Net revenue 100.0 % 100.0 % Cost of reven..."
03/03/2015 8-K Quarterly results
Docs: "Insys Therapeutics Reports Fourth Quarter and Year End 2014 Results"
11/14/2014 8-K Quarterly results, Conference call transcript
Docs: "Insys Therapeutics Reports Third Quarter 2014 Financial Results",
"Transcript of Conference Call on November 11, 2014"
08/12/2014 8-K Quarterly results
Docs: "Insys Therapeutics Reports Second Quarter 2014 Results"
05/13/2014 8-K Quarterly results
Docs: "Insys Therapeutics Reports First Quarter 2014 Results"
03/04/2014 8-K Quarterly results
Docs: "Insys Therapeutics Reports Fourth Quarter and Year End 2013 Results"
11/12/2013 8-K Form 8-K - Current report
08/13/2013 8-K Form 8-K - Current report
06/03/2013 8-K Form 8-K - Current report

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy